IRIS Registry study reveals decline in bevacizumab use
This IRIS Registry study assessed the use of bevacizumab among patients with Medicare fee-for-service health insurance between 2013 and 2019. Researchers used the IRIS Registry database to identify the volume and type of anti-VEGF agents injected at participating practices. The patient’s insurance status was recorded (Medicare fee for service, Medicare Advantage, and other insurance).

A total of 21,441,154 anti-VEGF injections were identified during this study period across all eye disease indications. There was a significant decline in bevacizumab use across all payers. The lowest relative utilization of bevacizumab has been consistently in the Medicare fee-for-service population.

This analysis demonstrates a significant decline in bevacizumab use and consistently lower use in the Medicare fee-for-service population. Medicare payment policy could be used to increase the proportion of patients treated with bevacizumab.

Source:https://www.aao.org/editors-choice/iris-registry-study-reveals-decline-in-bevacizumab
Like
Comment
Share